IP Library Granted Patent US 9,457,189
Granted Patent B2
US 9,457,189 · App. 14/704,500 · Granted Oct 4, 2016

Hypertension treatment device and method for mitigating rapid changes in blood pressure

Inventor: Martin A. Rossing (Coon Rapids, MN)
Assignee: CVRx, Inc.
A61N1/36167A61N1/36114A61N1/36117A61N1/36135
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,457,189
App. No.
14/704,500
Granted
Oct 4, 2016
Kind
B2
Abstract

An implantable baroreflex activation device administers a special electrotherapy program that causes the device to apply electrotherapy to limit a rate of change of blood pressure increase associated with a blood pressure surge event such as a morning blood pressure surge (MBPS).

Claims (8)

1. A method of programming an implantable baroreflex activation device, the method comprising:

programming the device with a nominal electrotherapy program configured to be administered to a patient by the device during an absence of an expected blood pressure surge event; and

programming the device with a special electrotherapy program configured to be administered to the patient during a predetermined time window, the predetermined time window extending from prior to the expected blood pressure surge event until after conclusion of the expected blood pressure surge event, the special electrotherapy program configured to affect the intrinsic circadian rhythm of the patient by limiting a rate of increase of blood pressure in the patient during the expected blood pressure surge event.

2. The method of claim 1 , wherein programming the device with a special electrotherapy program further comprises programming the device with a special electrotherapy program further configured to increase the level of electrotherapy as compared to a level provided during the nominal electrotherapy, so as to reduce the rate of increase of blood pressure in the patient during the expected blood pressure surge event.

3. The method of claim 1 , wherein programming the device with a special electrotherapy program further comprises programming the device with a special electrotherapy program further configured to reduce the level of electrotherapy prior to the expected blood pressure surge event, then subsequent to the start of the expected blood pressure surge event return the level of electrotherapy to a level provided during nominal electrotherapy, so as to reduce the rate of increase of blood pressure in the patient during the expected blood pressure surge event.

4. The method of claim 1 , wherein programming the device with a special electrotherapy program further comprises programming the device with a special electrotherapy program further configured to reduce the level of electrotherapy prior to the expected blood pressure surge event, then subsequent to the start of the expected blood pressure surge event increase the level of electrotherapy greater than a level provided during nominal electrotherapy, and by the conclusion of the expected blood pressure surge event return the level of electrotherapy to a level provided during nominal electrotherapy, so as to reduce the rate of increase of blood pressure in the patient during the expected blood pressure surge event.

5. The method of claim 1 , wherein programming the device with a special electrotherapy program further comprises programming the device with a special electrotherapy program further configured to based at least in part on information received from a sensor coupled to the implantable baroreflex activation device.

6. The method of claim 1 , wherein programming the device with a special electrotherapy program further comprises programming the device with a special electrotherapy program further configured to affect the intrinsic circadian rhythm of the patient by limiting a rate of increase of blood pressure in the patient during the expected blood pressure surge event.

Assignments (2)
SECURITY INTEREST Recorded Oct 31, 2022
From: CVRX, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
Reel/Frame 061824/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2015
From: ROSSING, MARTIN A.
To: CVRX, INC.
Reel/Frame 035772/0795 →
Continuity (2)
Division 11323565 · Dec 29, 2005
Related Publication 20150251009A1 · Sep 10, 2015